| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.97 | 0.002 | 0.97 | Aldehyde oxidase inhibitor | 0.169 0.124 DBMET01087 | ||
| 0.969 | 0.004 | 0.969 | Analgesic | |||
| 0.93 | 0.002 | 0.93 | Analgesic, opioid | |||
| 0.861 | 0.004 | 0.861 | Spasmolytic | 0.28 0.078 DBMET00181 | ||
| 0.776 | 0.003 | 0.776 | P-glycoprotein inhibitor | |||
| 0.738 | 0.005 | 0.738 | Hypoglycemic | |||
| 0.674 | 0.009 | 0.701 | 5 Hydroxytryptamine release stimulant | 0.701 0.007 DBMET00181 0.581 0.016 DBMET01087 | DBMET00181 | |
| 0.655 | 0.005 | 0.655 | Potassium channel (Voltage-sensitive) blocker | |||
| 0.646 | 0.004 | 0.646 | Glutamate receptor antagonist | |||
| 0.639 | 0.006 | 0.639 | HERG channel blocker | |||
| 0.615 | 0.005 | 0.615 | Psychostimulant | 0.17 0.1 DBMET00181 0.185 0.089 DBMET01087 | ||
| 0.557 | 0.003 | 0.557 | Opioid agonist | |||
| 0.557 | 0.003 | 0.557 | Opioid mu receptor agonist | |||
| 0.555 | 0.004 | 0.555 | Opioid antagonist | |||
| 0.546 | 0.004 | 0.546 | Cholinergic antagonist | 0.233 0.024 DBMET00181 0.325 0.012 DBMET01087 | ||
| 0.54 | 0.004 | 0.54 | Opioid mu receptor antagonist | |||
| 0.537 | 0.004 | 0.537 | Acetylcholine antagonist | 0.23 0.024 DBMET00181 0.323 0.012 DBMET01087 | ||
| 0.498 | 0.011 | 0.498 | Potassium channel blocker | 0.173 0.113 DBMET00181 | ||
| 0.454 | 0.004 | 0.454 | Acetylcholine nicotinic antagonist | 0.167 0.017 DBMET00181 0.363 0.005 DBMET01087 | ||
| 0.396 | 0.004 | 0.396 | Opioid kappa receptor antagonist | |||
| 0.335 | 0.004 | 0.335 | Neuronal nicotinic receptor antagonist | 0.092 0.028 DBMET00181 0.299 0.005 DBMET01087 | ||
| 0.353 | 0.025 | 0.353 | 5 Hydroxytryptamine uptake stimulant | 0.258 0.073 DBMET00181 0.25 0.08 DBMET01087 | ||
| 0.318 | 0.005 | 0.318 | NMDA receptor antagonist | |||
| 0.291 | 0.005 | 0.291 | Opioid delta receptor antagonist | |||
| 0.288 | 0.014 | 0.288 | Anesthetic local | |||
| 0.278 | 0.004 | 0.278 | Opioid delta receptor agonist | |||
| 0.258 | 0.047 | 0.258 | Anesthetic general | 0.134 0.132 DBMET01087 | ||
| 0.347 | 0.148 | 0.347 | Caspase 9 stimulant | 0.273 0.226 DBMET01087 | ||
| 0.255 | 0.064 | 0.267 | Tyrosine 3 hydroxylase inhibitor | 0.264 0.055 DBMET00181 0.267 0.053 DBMET01087 | DBMET01087 | |
| 0.327 | 0.137 | 0.327 | 5 Hydroxytryptamine release inhibitor | 0.29 0.177 DBMET01087 | ||
| 0.208 | 0.022 | 0.208 | Acetylcholine muscarinic antagonist | 0.127 0.061 DBMET00181 | ||
| 0.177 | 0.005 | 0.177 | Androgen agonist | 0.059 0.042 DBMET00181 0.059 0.042 DBMET01087 | ||
| 0.272 | 0.113 | 0.272 | Vasodilator, coronary | 0.202 0.18 DBMET00181 | ||
| 0.207 | 0.051 | 0.209 | 5 Hydroxytryptamine 3E antagonist | 0.199 0.063 DBMET00181 0.209 0.049 DBMET01087 | DBMET01087 | |
| 0.28 | 0.13 | 0.354 | GABA C receptor rho-3 antagonist | 0.354 0.083 DBMET00181 0.341 0.09 DBMET01087 | DBMET00181 | |
| 0.172 | 0.033 | 0.172 | Cathepsin H inhibitor | 0.103 0.102 DBMET01087 | ||
| 0.162 | 0.026 | 0.162 | Falcipain inhibitor | |||
| 0.166 | 0.03 | 0.166 | Falcipain 3 inhibitor | |||
| 0.184 | 0.049 | 0.184 | Arachidonic acid antagonist | 0.148 0.091 DBMET01087 | ||
| 0.158 | 0.025 | 0.158 | Falcipain 2 inhibitor | |||
| 0.271 | 0.14 | 0.271 | Histamine release inhibitor | |||
| 0.219 | 0.095 | 0.219 | DNA synthesis inhibitor | |||
| 0.31 | 0.199 | 0.361 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.309 0.201 DBMET00181 0.361 0.139 DBMET01087 | DBMET01087 | |
| 0.169 | 0.059 | 0.169 | Acetylcholine M1 receptor antagonist | |||
| 0.157 | 0.054 | 0.157 | Neurotrophic factor | |||
| 0.175 | 0.076 | 0.175 | Lipocortins synthesis antagonist | 0.134 0.132 DBMET00181 0.151 0.103 DBMET01087 | ||
| 0.15 | 0.054 | 0.15 | Nav1.6 sodium channel blocker | |||
| 0.213 | 0.129 | 0.213 | Gastrin inhibitor | 0.203 0.145 DBMET01087 | ||
| 0.167 | 0.084 | 0.167 | Succinate dehydrogenase inhibitor | 0.139 0.134 DBMET01087 | ||
| 0.118 | 0.036 | 0.118 | Calcium antagonist | |||
| 0.14 | 0.061 | 0.14 | Alpha-N-acetylglucosaminidase inhibitor | 0.125 0.073 DBMET01087 | ||
| 0.142 | 0.066 | 0.143 | Ca2+-transporting ATPase inhibitor | 0.143 0.062 DBMET00181 0.14 0.074 DBMET01087 | DBMET00181 | |
| 0.1 | 0.024 | 0.1 | Estrogen-related receptor beta agonist | |||
| 0.221 | 0.147 | 0.276 | Cholesterol antagonist | 0.276 0.107 DBMET00181 0.214 0.153 DBMET01087 | DBMET00181 | |
| 0.123 | 0.051 | 0.123 | Aminopeptidase B inhibitor | |||
| 0.224 | 0.153 | 0.224 | Apoptosis antagonist | |||
| 0.194 | 0.124 | 0.194 | Superoxide dismutase inhibitor | 0.173 0.152 DBMET01087 | ||
| 0.11 | 0.046 | 0.119 | Prolactin inhibitor | 0.119 0.039 DBMET00181 0.084 0.074 DBMET01087 | DBMET00181 | |
| 0.101 | 0.042 | 0.101 | Glutamate release inhibitor | |||
| 0.108 | 0.051 | 0.108 | Sphingomyelinase inhibitor | |||
| 0.078 | 0.021 | 0.078 | Acetyl-CoA transferase inhibitor | |||
| 0.191 | 0.136 | 0.191 | Neuropeptide Y2 antagonist | |||
| 0.116 | 0.062 | 0.116 | Photosensitizer | 0.103 0.082 DBMET01087 | ||
| 0.108 | 0.056 | 0.108 | Adenylate kinase inhibitor | |||
| 0.069 | 0.018 | 0.069 | Nicotinic alpha3beta2 receptor antagonist | 0.059 0.028 DBMET00181 0.058 0.029 DBMET01087 | ||
| 0.076 | 0.026 | 0.076 | Caspase 9 inhibitor | |||
| 0.117 | 0.068 | 0.117 | Calcium channel N-type blocker | |||
| 0.136 | 0.089 | 0.136 | Adenylate cyclase stimulant | |||
| 0.211 | 0.164 | 0.211 | Vasodilator, peripheral | 0.192 0.186 DBMET01087 | ||
| 0.103 | 0.058 | 0.103 | Anabolic | 0.1 0.063 DBMET01087 | ||
| 0.123 | 0.08 | 0.123 | Vanilloid 1 agonist | |||
| 0.07 | 0.027 | 0.07 | Acyl-CoA dehydrogenase inhibitor | |||
| 0.112 | 0.07 | 0.112 | Microtubule formation inhibitor | |||
| 0.049 | 0.008 | 0.049 | Benzodiazepine receptor peripheral-type antagonist | |||
| 0.098 | 0.056 | 0.098 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.091 0.064 DBMET01087 | ||
| 0.082 | 0.041 | 0.082 | Aminopeptidase I inhibitor | |||
| 0.064 | 0.025 | 0.064 | Acetyl-CoA transferase 2 inhibitor | |||
| 0.173 | 0.137 | 0.173 | Immunostimulant | |||
| 0.051 | 0.017 | 0.051 | G protein-coupled receptor agonist | |||
| 0.16 | 0.126 | 0.16 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | |||
| 0.102 | 0.069 | 0.129 | Ferrochelatase inhibitor | 0.128 0.048 DBMET00181 0.129 0.048 DBMET01087 | DBMET01087 | |
| 0.035 | 0.006 | 0.035 | Protease (Human cytomegalovirus) inhibitor | |||
| 0.112 | 0.084 | 0.112 | Nav1.3 sodium channel blocker | |||
| 0.194 | 0.166 | 0.194 | Insulysin inhibitor | |||
| 0.076 | 0.049 | 0.076 | Glutamate dehydrogenase inhibitor | |||
| 0.115 | 0.089 | 0.115 | Nav1.2 sodium channel blocker | |||
| 0.075 | 0.05 | 0.075 | Vanilloid 4 agonist | |||
| 0.103 | 0.08 | 0.106 | Acetylcholine release stimulant | 0.106 0.074 DBMET01087 | DBMET01087 | |
| 0.062 | 0.038 | 0.062 | Cathepsin E inhibitor | |||
| 0.033 | 0.011 | 0.033 | Estrogen-related receptor gamma antagonist | |||
| 0.092 | 0.069 | 0.092 | Interleukin 1 beta converting enzyme inhibitor | |||
| 0.17 | 0.148 | 0.17 | Calpain inhibitor | |||
| 0.091 | 0.07 | 0.091 | Creatine kinase inhibitor | |||
| 0.088 | 0.067 | 0.088 | Uric acid excretion stimulant | |||
| 0.058 | 0.038 | 0.058 | Argininosuccinate synthase inhibitor | |||
| 0.038 | 0.018 | 0.038 | Histone deacetylase 4 inhibitor | |||
| 0.034 | 0.018 | 0.034 | Peptide deformylase inhibitor | |||
| 0.039 | 0.024 | 0.039 | Nicotinic receptor beta4 subunit antagonist | |||
| 0.035 | 0.022 | 0.035 | Calcium-independent phospholipase A2 inhibitor | |||
| 0.071 | 0.058 | 0.071 | CYP2A6 inhibitor | |||
| 0.082 | 0.07 | 0.082 | Granulocyte macrophage colony stimulating factor agonist | 0.082 0.07 DBMET01087 | ||
| 0.088 | 0.076 | 0.088 | Lanosterol 14 alpha demethylase inhibitor | |||
| 0.034 | 0.023 | 0.034 | Histone deacetylase 2 inhibitor | 0.033 0.024 DBMET00181 | ||
| 0.045 | 0.035 | 0.045 | Baculoviral IAP repeat-containing protein inhibitor | |||
| 0.03 | 0.02 | 0.03 | Histone deacetylase 10 inhibitor | |||
| 0.064 | 0.055 | 0.108 | Elastase 1 inhibitor | 0.108 0.016 DBMET00181 | DBMET00181 | |
| 0.139 | 0.13 | 0.139 | Phospholipase C inhibitor | |||
| 0.06 | 0.052 | 0.06 | Protease 3C (Human rhinovirus) inhibitor | |||
| 0.067 | 0.059 | 0.067 | Phospholipase D inhibitor | |||
| 0.022 | 0.014 | 0.022 | Vitamin D receptor antagonist | |||
| 0.038 | 0.03 | 0.038 | Cathepsin L2 inhibitor | |||
| 0.068 | 0.06 | 0.096 | Acetylcholine M4 receptor antagonist | 0.096 0.031 DBMET00181 | DBMET00181 | |
| 0.025 | 0.018 | 0.025 | Vanilloid 2 agonist | |||
| 0.055 | 0.048 | 0.055 | Acetylcholine M3 receptor antagonist | |||
| 0.039 | 0.034 | 0.039 | Kainate receptor agonist | |||
| 0.049 | 0.044 | 0.049 | Human rhinovirus A protease inhibitor | |||
| 0.161 | 0.157 | 0.168 | Interleukin agonist | 0.168 0.151 DBMET01087 | DBMET01087 | |
| 0.026 | 0.023 | 0.026 | Nicotinic alpha4beta2 receptor agonist | |||
| 0.022 | 0.019 | 0.022 | Histone deacetylase 3 inhibitor | |||
| 0.027 | 0.025 | 0.029 | Histone deacetylase class IV inhibitor | 0.029 0.024 DBMET00181 | DBMET00181 | |
| 0.027 | 0.025 | 0.029 | Histone deacetylase 11 inhibitor | 0.029 0.024 DBMET00181 | DBMET00181 | |
| 0.025 | 0.024 | 0.025 | Baculoviral IAP repeat-containing protein 4 inhibitor | |||
| 0.092 | 0.091 | 0.129 | GABA C receptor antagonist | 0.129 0.044 DBMET01087 | DBMET01087 | |
| 0.063 | 0.062 | 0.063 | Catalase inhibitor | |||
| 0.122 | 0.122 | 0.138 | Pregnane X receptor agonist | 0.138 0.078 DBMET00181 | DBMET00181 | |
| 0.088 | 0.103 | 0.095 | DOPA decarboxylase inhibitor | 0.095 0.087 DBMET01087 | DBMET01087 | |
| 0.057 | 0.074 | 0.063 | Glutamate (mGluR7) antagonist | 0.063 0.058 DBMET00181 | DBMET00181 | |
| 0.042 | 0.06 | 0.057 | Elastase inhibitor | 0.057 0.033 DBMET00181 | DBMET00181 | |
| 0.136 | 0.161 | 0.146 | Neurotrophic factor enhancer | 0.146 0.144 DBMET01087 | DBMET01087 | |
| 0.062 | 0.093 | 0.072 | Glycine receptor antagonist | 0.072 0.07 DBMET01087 | DBMET01087 | |
| 0.027 | 0.068 | 0.048 | Guanylate cyclase inhibitor | 0.048 0.023 DBMET01087 | DBMET01087 | |
| 0.109 | 0.154 | 0.172 | GABA C receptor rho-2 antagonist | 0.127 0.112 DBMET00181 0.172 0.049 DBMET01087 | DBMET01087 | |
| 0.147 | 0.195 | 0.281 | 5 Hydroxytryptamine 1E antagonist | 0.281 0.044 DBMET00181 0.259 0.065 DBMET01087 | DBMET00181 | |
| 0.071 | 0.122 | 0.122 | GABA C receptor rho-1 antagonist | 0.122 0.038 DBMET01087 | DBMET01087 | |
| 0.037 | 0.091 | 0.059 | Acetylcholine M5 receptor antagonist | 0.059 0.043 DBMET00181 | DBMET00181 | |
| 0.066 | 0.127 | 0.101 | GABA C receptor agonist | 0.101 0.066 DBMET01087 | DBMET01087 | |
| 0.035 | 0.102 | 0.053 | Sphingosine kinase 2 inhibitor | 0.053 0.042 DBMET01087 | DBMET01087 | |
| 0.051 | 0.119 | 0.072 | Potassium channel (Tandem pore domain) blocker | 0.072 0.057 DBMET00181 0.072 0.058 DBMET01087 | DBMET01087 | |
| 0.033 | 0.104 | 0.052 | Cytokine production stimulant | 0.052 0.025 DBMET01087 | DBMET01087 | |
| 0.066 | 0.142 | 0.087 | Electrolyte absorption antagonist | 0.087 0.079 DBMET01087 | DBMET01087 | |
| 0.05 | 0.126 | 0.059 | Prolactin release inhibitor | 0.059 0.055 DBMET00181 | DBMET00181 | |
| 0.04 | 0.122 | 0.055 | Pregnane X receptor antagonist | 0.055 0.045 DBMET01087 | DBMET01087 | |
| 0.1 | 0.195 | 0.136 | Interferon gamma antagonist | 0.136 0.1 DBMET01087 | DBMET01087 | |
| 0.154 | 0.261 | 0.202 | Sodium/bile acid cotransporter inhibitor | 0.202 0.185 DBMET01087 | DBMET01087 | |
| 0.083 | 0.207 | 0.185 | Sigma receptor agonist | 0.185 0.067 DBMET00181 | DBMET00181 | |
| 0.03 | 0.166 | 0.089 | Nicotinic alpha4beta2 receptor antagonist | 0.069 0.064 DBMET00181 0.089 0.041 DBMET01087 | DBMET01087 | |
| 0.125 | 0.271 | 0.214 | RNA-directed DNA polymerase inhibitor | 0.214 0.081 DBMET01087 | DBMET01087 | |
| 0.088 | 0.252 | 0.133 | CF transmembrane conductance regulator agonist | 0.133 0.111 DBMET01087 | DBMET01087 | |
| 0.006 | 0.171 | 0.036 | Endothelial nitric-oxide synthase inhibitor | 0.036 0.016 DBMET01087 | DBMET01087 | |
| 0.006 | 0.19 | 0.029 | Imidazoline I1 receptor antagonist | 0.019 0.018 DBMET00181 0.029 0.007 DBMET01087 | DBMET01087 | |
| 0.016 | 0.202 | 0.036 | Tryptophan 5 hydroxylase inhibitor | 0.036 0.024 DBMET01087 | DBMET01087 | |
| 0.122 | 0.32 | 0.184 | Nitric-oxide synthase stimulant | 0.184 0.119 DBMET01087 | DBMET01087 | |
| 0.136 | 0.337 | 0.229 | Interleukin 2 agonist | 0.226 0.148 DBMET00181 0.229 0.144 DBMET01087 | DBMET01087 | |
| 0.137 | 0.358 | 0.24 | Ca(v)3.3 blocker | 0.218 0.155 DBMET00181 0.24 0.117 DBMET01087 | DBMET01087 | |
| 0.044 | 0.272 | 0.088 | mTOR complex 2 inhibitor | 0.088 0.051 DBMET01087 | DBMET01087 | |
| 0.035 | 0.272 | 0.091 | Nitric-oxide synthase inhibitor | 0.091 0.076 DBMET01087 | DBMET01087 | |
| 0.006 | 0.27 | 0.028 | Potassium channel subfamily K member 3 blocker | 0.028 0.024 DBMET00181 | DBMET00181 | |
| 0.033 | 0.301 | 0.112 | 5 Hydroxytryptamine 3A agonist | 0.112 0.063 DBMET01087 | DBMET01087 | |
| 0.021 | 0.306 | 0.091 | Inducible nitric-oxide synthase inhibitor | 0.091 0.046 DBMET01087 | DBMET01087 | |
| 0.003 | 0.338 | 0.024 | Angiotensin AT1A receptor antagonist | 0.024 0.01 DBMET00181 | DBMET00181 | |
| 0.031 | 0.41 | 0.109 | Bromodomain-containing protein 2 inhibitor | 0.087 0.06 DBMET00181 0.109 0.031 DBMET01087 | DBMET01087 | |
| 0.007 | 0.491 | 0.035 | Tryptophan hydroxylase 1 inhibitor | 0.026 0.004 DBMET00181 0.035 0.003 DBMET01087 | DBMET01087 | |
| 0.043 | 0.541 | 0.166 | Histone acetyltransferase inhibitor | 0.166 0.118 DBMET00181 | DBMET00181 | |
| 0.077 | 0.658 | 0.178 | ErbB-1 antagonist | 0.178 0.119 DBMET00181 | DBMET00181 | |
| 0.016 | 0.706 | 0.114 | Alpha 2d adrenoreceptor antagonist | 0.114 0.029 DBMET01087 | DBMET01087 | |
| 0.016 | 0.709 | 0.172 | ErbB-3 antagonist | 0.172 0.014 DBMET00181 | DBMET00181 | |
| 0.004 | 0.76 | 0.053 | Bromodomain-containing protein 3 inhibitor | 0.053 0.029 DBMET01087 | DBMET01087 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |